Entera Bio Ltd (ENTX)

$1.83 +0.03 (1.67%)
Market Cap 82.19M
Revenue (ttm) 180,000.00
Net Income (ttm) -9.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -5,300.00%
Debt to Equity Ratio 0.00
Volume 125,200
Avg Vol 158,422
Day's Range N/A - N/A
Shares Out 45.66M
Stochastic %K 7%
Beta 1.69
Analysts Sell
Price Target $10.00

Company Profile

Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis;...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 532 7151
Address:
Kiryat Hadassah Minrav Building, Fifth Floor, Jerusalem, Israel
tymtested
tymtested Sep. 15 at 8:21 PM
$ENTX with such a small MC ... should OPKO just buy this company,,, assuming there is real potential.
0 · Reply
WallStWireAds
WallStWireAds Sep. 15 at 1:37 PM
$ENTX https://caplynx.io/407Sr8o
0 · Reply
WallStWireAds
WallStWireAds Sep. 8 at 2:25 PM
$ENTX
0 · Reply
WallStWireAds
WallStWireAds Sep. 8 at 12:32 PM
$ENTX https://caplynx.io/BD38j7x
0 · Reply
tymtested
tymtested Sep. 6 at 1:02 AM
$ENTX another presentation on Sunday.
0 · Reply
neangewo
neangewo Sep. 5 at 7:57 PM
$ENTX Looks like probably no news until Monday.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 5:11 PM
$ENTX Great piece that accurately captures ENTX's current position. So if you want to refresh your understanding of ENTX or learn about ENTX for the first time, this is essential reading. https://beyondspx.com/quote/ENTX/entera-bio-s-oral-revolution-unlocking-peptide-potential-beyond-the-needle-nasdaq-entx#analysis
0 · Reply
tymtested
tymtested Sep. 4 at 11:34 AM
$ENTX anyone interested in presentation on 9-5?
1 · Reply
SweetHome
SweetHome Sep. 3 at 6:17 PM
$ENTX Volume isn’t impressive but obviously more buyers than sellers today.
0 · Reply
YoloAlfred
YoloAlfred Sep. 3 at 4:57 PM
$ENTX 🤔🤔🤔🤔
0 · Reply
Latest News on ENTX
Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

Aug 8, 2025, 4:05 PM EDT - 5 weeks ago

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

Jul 28, 2025, 7:30 AM EDT - 7 weeks ago

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

May 9, 2025, 4:05 PM EDT - 4 months ago

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

Mar 28, 2025, 4:05 PM EDT - 6 months ago

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

Mar 17, 2025, 8:00 AM EDT - 6 months ago

OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

Entera Bio to Participate in Upcoming Events

Feb 24, 2025, 8:30 AM EST - 7 months ago

Entera Bio to Participate in Upcoming Events

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 27, 2025, 8:00 AM EST - 8 months ago

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

Nov 8, 2024, 4:05 PM EST - 11 months ago

Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Entera Bio to Participate in Upcoming Investor and Scientific Conferences

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

Aug 9, 2024, 4:05 PM EDT - 1 year ago

Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

May 15, 2024, 8:00 AM EDT - 1 year ago

Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

May 13, 2024, 7:00 AM EDT - 1 year ago

Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

May 10, 2024, 4:10 PM EDT - 1 year ago

Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Apr 8, 2024, 8:30 AM EDT - 1 year ago

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Mar 26, 2024, 8:30 AM EDT - 1 year ago

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Mar 20, 2024, 8:00 AM EDT - 1 year ago

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Mar 8, 2024, 4:05 PM EST - 1 year ago

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mar 4, 2024, 8:30 AM EST - 1 year ago

Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 30, 2024, 8:30 AM EST - 1 year ago

Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

Jan 3, 2024, 8:00 AM EST - 1 year ago

Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

Dec 26, 2023, 8:00 AM EST - 1 year ago

Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Nov 29, 2023, 8:30 AM EST - 1 year ago

Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Nov 14, 2023, 7:30 AM EST - 1 year ago

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Nov 9, 2023, 2:30 PM EST - 2 years ago

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting

Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

Sep 12, 2023, 8:30 AM EDT - 2 years ago

Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

Entera Bio to Participate in Upcoming Investor Conferences

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Entera Bio to Participate in Upcoming Investor Conferences

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Aug 16, 2023, 8:30 AM EDT - 2 years ago

Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

Aug 11, 2023, 4:05 PM EDT - 2 years ago

Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

Jun 7, 2023, 7:30 AM EDT - 2 years ago

Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors

Entera Bio Announces Q1 2023 Financial Results and Corporate Updates

May 5, 2023, 4:05 PM EDT - 2 years ago

Entera Bio Announces Q1 2023 Financial Results and Corporate Updates

Entera's Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

May 3, 2023, 9:34 AM EDT - 2 years ago

Entera's Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera's Clinical and Scientific Advisory Board

Apr 26, 2023, 8:30 AM EDT - 2 years ago

Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera's Clinical and Scientific Advisory Board

Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program

Apr 3, 2023, 7:00 AM EDT - 2 years ago

Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

Mar 31, 2023, 4:00 PM EDT - 2 years ago

Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022

Entera Bio Regains Compliance with Nasdaq Listing Requirements

Mar 23, 2023, 9:27 AM EDT - 2 years ago

Entera Bio Regains Compliance with Nasdaq Listing Requirements

Entera Bio Announces FDA's Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

Feb 15, 2023, 10:00 AM EST - 2 years ago

Entera Bio Announces FDA's Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

Entera Bio to Participate in the SVB Securities Global Biopharma Conference

Feb 13, 2023, 9:00 AM EST - 2 years ago

Entera Bio to Participate in the SVB Securities Global Biopharma Conference

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

Nov 10, 2022, 4:15 PM EST - 3 years ago

Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

Oct 6, 2022, 7:00 AM EDT - 3 years ago

Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis

Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613's Potential Impact on Wednesday, September 28th @ 10am ET

Sep 21, 2022, 8:30 AM EDT - 3 years ago

Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613's Potential Impact on Wednesday, September 28th @ 10am ET

Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

Sep 12, 2022, 4:30 PM EDT - 3 years ago

Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference

Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

Sep 12, 2022, 6:30 AM EDT - 3 years ago

Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting

Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

Aug 11, 2022, 6:30 AM EDT - 3 years ago

Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022

Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting

Jul 26, 2022, 7:30 AM EDT - 3 years ago

Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting

Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO

Jul 18, 2022, 9:23 AM EDT - 3 years ago

Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO

Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

Jul 18, 2022, 7:05 AM EDT - 3 years ago

Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company's President of Research & Development to Pursue Outside Opportunities

Jun 17, 2022, 5:00 PM EDT - 3 years ago

Entera Bio Announces Departure of Dr. Phillip Schwartz, the Company's President of Research & Development to Pursue Outside Opportunities

Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q1 2022 Results - Earnings Call Transcript

May 18, 2022, 2:34 PM EDT - 3 years ago

Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q1 2022 Results - Earnings Call Transcript

tymtested
tymtested Sep. 15 at 8:21 PM
$ENTX with such a small MC ... should OPKO just buy this company,,, assuming there is real potential.
0 · Reply
WallStWireAds
WallStWireAds Sep. 15 at 1:37 PM
$ENTX https://caplynx.io/407Sr8o
0 · Reply
WallStWireAds
WallStWireAds Sep. 8 at 2:25 PM
$ENTX
0 · Reply
WallStWireAds
WallStWireAds Sep. 8 at 12:32 PM
$ENTX https://caplynx.io/BD38j7x
0 · Reply
tymtested
tymtested Sep. 6 at 1:02 AM
$ENTX another presentation on Sunday.
0 · Reply
neangewo
neangewo Sep. 5 at 7:57 PM
$ENTX Looks like probably no news until Monday.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 5:11 PM
$ENTX Great piece that accurately captures ENTX's current position. So if you want to refresh your understanding of ENTX or learn about ENTX for the first time, this is essential reading. https://beyondspx.com/quote/ENTX/entera-bio-s-oral-revolution-unlocking-peptide-potential-beyond-the-needle-nasdaq-entx#analysis
0 · Reply
tymtested
tymtested Sep. 4 at 11:34 AM
$ENTX anyone interested in presentation on 9-5?
1 · Reply
SweetHome
SweetHome Sep. 3 at 6:17 PM
$ENTX Volume isn’t impressive but obviously more buyers than sellers today.
0 · Reply
YoloAlfred
YoloAlfred Sep. 3 at 4:57 PM
$ENTX 🤔🤔🤔🤔
0 · Reply
Indyshaw
Indyshaw Aug. 28 at 12:49 PM
$OPK $ENTX Good to see more data being presented by Entero on the GLP-2 tablets.
1 · Reply
WallStWireAds
WallStWireAds Aug. 28 at 12:04 PM
$ENTX https://caplynx.io/HWjTt46
0 · Reply
NotTheJuan
NotTheJuan Aug. 22 at 5:55 PM
$ENTX expecting a breakout from this wedge soon. Targeting 6.00 - 8.00 range.
0 · Reply
WallStWireAds
WallStWireAds Aug. 21 at 11:04 AM
$ENTX Following Viking Therapeutics’ Read-Out, Is Entera Bio the Oral Platform Play Everyone’s Missing? (NASDAQ: ENTX) https://newsblaze.com/business/finance/following-vikings-therapeutics-read-out-is-entera-bio-the-oral-platform-play-everyones-missing-nasdaq-entx_207069/
0 · Reply
WallStWireAds
WallStWireAds Aug. 13 at 4:12 AM
$ENTX https://venture-block.com/meet-entera-bio-the-85m-company-that-could-solve-big-pharmas-oral-glp-1-problem/
0 · Reply
d_risk
d_risk Aug. 9 at 1:08 AM
$ENTX - Entera Bio Ltd. Ordinary Shares - 10Q - Updated Risk Factors ENTX flags new risks from Israel’s escalating regional conflict, noting key research and management staff are based there, making the company vulnerable to Middle East instability despite core operations being elsewhere. #Biotechnology #ManagementRisk #ResearchOperations #MiddleEastConflict #GeopoliticalRisk 🟢 Added 🟠 Removed https://d-risk.ai/ENTX/10-Q/2025-08-08
0 · Reply
SweetHome
SweetHome Aug. 4 at 2:36 PM
$ENTX https://thefinanceherald.com/microcap-reportentera-bio-is-developing-the-first-pill-to-replace-painful-daily-injections-for-200-million-women/
0 · Reply
WallStWireAds
WallStWireAds Aug. 3 at 11:31 PM
$ENTX https://thefinanceherald.com/microcap-reportentera-bio-is-developing-the-first-pill-to-replace-painful-daily-injections-for-200-million-women/
0 · Reply
bioland
bioland Jul. 30 at 5:19 PM
$ENTX Small position here...and trying to see how this goes higher when P3 data will be 2 years out?
0 · Reply
GarbageLoverHere
GarbageLoverHere Jul. 29 at 9:59 PM
$ENTX great news to not even move. it doesn’t matter what happens this dies and dies and dies
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 29 at 3:06 PM
$ENTX pt 2.5
0 · Reply
Indyshaw
Indyshaw Jul. 29 at 11:51 AM
$OPK starting to look at OPK as a well performing mutual fund with holdings like $WGS and $ENTX Here’s to Thursday being more good news.
1 · Reply